Hu, Yun
Paris, Sébastien
Barsoumian, Hampartsoum
Abana, Chike O.
He, Kewen
Sezen, Duygu
Wasley, Mark
Masrorpour, Fatemeh
Chen, Dawei
Yang, Liangpeng
Dunn, Joe D.
Gandhi, Saumil
Nguyen, Quynh-Nhu
Cortez, Maria Angelica
Welsh, James W.
Article History
Received: 15 October 2021
Accepted: 23 November 2021
First Online: 11 December 2021
Declarations
:
: All animal procedures were approved by the Institutional Animal Care and Use Committee at MD Anderson Cancer Center.
: We understand that the text and any pictures published in the article will be freely available on the internet and may be seen by the general public. The pictures and text may also appear on other websites or in print, may be translated into other languages or used for commercial purposes.
: JW receives research support from GlaxoSmithKline, Bristol-Meyers Squibb, Merck, Nanobiotix, Mavu Pharmaceuticals, and Checkmate Pharmaceuticals; serves on the scientific advisory board for RefleXion Medical, MolecularMatch, OncoResponse, CheckMate, Mavu Pharmaceuticals, and Alpine Immune Sciences; is cofounder of Helios Oncology, MolecularMatch, and OncoResponse; is an advisor to AstraZeneca, Merck, MolecularMatch, Incyte, Aileron, and Nanobiotix; and holds patents for MP470 (amuvatinib), MRX34 regulation of PDL1, and RadScopal, an XRT technique to overcome immune resistance (MD Anderson Cancer Center has a trademark for RadScopal). SP is an employee of Nanobiotix.